A 72.2% confirmed objective response rate in first-line RAS-mutated metastatic colorectal cancer is not a number that gets ignored — standard-of-care arms in the same randomized Phase 2 trial came in at 43.2%, and the progression-free survival hazard ratio of 0.38 against FOLFIRI/bevacizumab carries a p-value below 0.05. That gap is the entire thesis behind Cardiff Oncology’s decision to move onvansertib, its oral PLK1 inhibitor, into a Phase 3 registrational trial. The FDA End-of-Phase 2 meeting has already locked in the dose and backbone: 30 mg onvansertib combined with FOLFIRI/bevacizumab.
The design choice matters clinically. Selecting FOLFIRI/bev over FOLFOX/bev as the Phase 3 backbone is a direct read-through from the Phase 2 data, where the 30 mg arm paired with FOLFIRI/bev showed the cleaner efficacy signal. PLK1 inhibition and oxaliplatin-based regimens appear to offer less combinatorial lift — at least in this dataset. Cardiff will present the full updated CRDF-004 data in a rapid oral session at ASCO between May 29 and June 2, which means the oncology community gets its first detailed look at subgroup behavior, duration of response, and likely some early survival shape before Phase 3 enrollment criteria are published.
The cash position deserves direct scrutiny. Cardiff held $46.1 million as of March 31, burning approximately $12.3 million in operating cash that quarter. The company projects runway into Q1 2027 — roughly three quarters. That timeline does not comfortably fund a Phase 3 enrollment ramp in a disease area where RAS-mutated mCRC trials routinely require hundreds of patients across global sites. Cardiff will need to raise capital or secure a partnership before Phase 3 opens, and the ASCO presentation is the clearest near-term opportunity to set those terms from a position of data strength rather than necessity.
The one marker that determines everything here is the duration-of-response data Cardiff presents at ASCO. Impressive ORR and a strong PFS hazard ratio are compelling, but if median PFS in the onvansertib arm has not reached maturity or shows early plateau decay, the Phase 3 overall survival endpoint becomes harder to power convincingly — and that directly affects how aggressively a potential partner prices any licensing discussion this summer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
